Location : Home > Products > Inhibitors of Meditech > Others
Name:BVT 2733
| Chemical structure | Code NO. |
MT0746 |
 |
Name |
BVT 2733 |
Synonym |
BVT2733; BVT-2733 | |
CAS NO. |
376640-41-4 | |
Chemical Formula |
C17H21ClN4O3S2 | |
MW |
428.96 | |
Purity |
>98% | |
Solubility(R.T.: 25℃) |
DMSO:8mg/mL | |
Stability |
- 20℃, 2 years |
Availability and price
BVT 2733 is in stock. Bulk available at low price, welcom to inquire quotation.
We offer big discount for bulk quantities. If you have any other questions or needs, please send email to sales@meditechbs.com. We’ll reply you asap.
Description
BVT 2733 is a new, small molecule, non-steroidal, isoform-selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
IC50 value:
Target: 11β-HSD1 inhibitor
in vitro:
in vivo: BVT 2733 lowered hepatic PEPCK and glucose-6-phosphatase mRNA, blood glucose and serum insulin concentrations compared with vehicle treated mice [1]. CIA mice were treated with BVT-2733 (100 mg/kg, orally) or vehicle twice daily for 2 weeks. BVT-2733 treatment attenuated the arthritis severity and anti-CII level in CIA mice. BVT-2733 also decreased the levels of serum TNF-α, IL-1β, IL-6 and IL-17. BVT-2733 treatment also significantly reduced synovial inflammation and joint destruction [2]. Mice receiving BVT 2733 treatment exhibited decreased body weight and enhanced glucose tolerance and insulin sensitivity compared to control mice. BVT 2733 also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo [3].
IC50 value:
Target: 11β-HSD1 inhibitor
in vitro:
in vivo: BVT 2733 lowered hepatic PEPCK and glucose-6-phosphatase mRNA, blood glucose and serum insulin concentrations compared with vehicle treated mice [1]. CIA mice were treated with BVT-2733 (100 mg/kg, orally) or vehicle twice daily for 2 weeks. BVT-2733 treatment attenuated the arthritis severity and anti-CII level in CIA mice. BVT-2733 also decreased the levels of serum TNF-α, IL-1β, IL-6 and IL-17. BVT-2733 treatment also significantly reduced synovial inflammation and joint destruction [2]. Mice receiving BVT 2733 treatment exhibited decreased body weight and enhanced glucose tolerance and insulin sensitivity compared to control mice. BVT 2733 also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo [3].
References
Attention
Sold for research purposes only; not for human use of any kind.
